AST SpaceMobile (NASDAQ: ASTS) closed at $58 on October 2, marking a 31% decline from its early July levels as a series of negative catalysts eroded investor confidence.

The steepest single-session drop came on July 16, when shares lost 17% following a dual announcement that rattled markets and reset expectations for the company’s growth trajectory.

On July 15, AST SpaceMobile disclosed a $1 billion convertible notes offering, a debt instrument that allows holders to swap their positions into equity at a later date.

Alongside that financing, the company pushed back its target of placing 45 satellites into orbit, shifting the deadline from the end of 2026 to early 2027 and delaying a key commercial milestone.

CFO Andy Johnson defended the terms of the deal on the subsequent earnings call, stating: “The notes have our lowest coupon ever at 1.625%, providing cost-efficient capital with effective dilution of less than 2%.”

Despite that argument, the combination of new dilution risk and a delayed operational timeline proved too much for the market to absorb in a single session.

Shares recovered ground through early August, climbing back to $72 by August 7, before running into further turbulence when second-quarter results were released on August 10.

Revenue for the quarter came in at $31.52 million, missing the consensus estimate of $34.98 million, while a $125.9 million write-off related to BlueBird 7, net of related insurance recoveries, dramatically widened losses.

The net loss attributable to common stockholders reached $230.91 million for the quarter, compared to $99.39 million during the same period a year earlier, a deterioration that compounded pressure on the stock.

BofA Global Research responded by cutting its price target to $80 from $95, while UBS trimmed its target to $78 from $80, both revisions coming on August 11 in the immediate aftermath of the earnings miss.

Despite those cuts, Wall Street’s collective view on AST SpaceMobile has remained broadly constructive, with analyst coverage actually expanding during the period of the stock’s decline.

The mean analyst price target slipped only modestly, from $81 on June 30 to $78 following the financing and earnings miss, even as the stock dropped from $89 to $58 over the same stretch.

Twelve analysts now publish price targets on the stock, up from nine previously, with the highest individual target sitting at $108, reflecting ongoing conviction among some on the Street.

The current ratings breakdown stands at 4 buys, 1 outperform, 7 holds, 1 underperform, and 1 sell, a modest shift from the 2 buys, 7 holds, and 2 underperforms recorded on June 30.

At $58, the stock trades 33% below the mean analyst target of $78, a gap that reflects either a buying opportunity or a sign that targets have yet to fully adjust to the company’s evolving risk profile.